|
|
 |
|
SBH Sciences' fully biologically active soluble Fas Ligand
SBH Sciences recently developed an efficient process for the production of
Recombinant soluble Fas Ligand.
Our soluble Fas Ligand (sFasL) corresponding to the entire extracellular domain of Fas Ligand (FasL) was found to induce significant levels of apoptosis in the absence of any cross-linking. We have shown that human Jurkat cells that express a moderate level of Fas endogenously were efficiently killed by SBH soluble FasL (ED50= 1-5 ng/ml).
Therapeutic Potential of soluble Fas Ligand
Recently there has been considerable interest in the role of Fas/FasL interactions in the immunologically privileged sites in the body such as the hamster cheek pounch, brain, ovary, testis, pregnant uterus, placenta and eye. FasL is important in the maintenance of immune privilege by killing invading inflammatory cells.
More complete understanding of the interaction between FasL, functional soluble FasL and the other mediators of immune privilege will be important to solving the problems of transplantation and understand the mechanisms of tumor escape. It may be important to check whether our product, the functional sFasL, can be added to the transplants to avoid immune attack and guarantee successful transplantation without tissue matching or immunosuppressive therapy.
Human peripheral T cells activated with phorbol myristic acetate and ionomycin also produced functional sFasL, suggesting that another application for human sFasL can be as a pathological agent in systemic tissue injury. The recombinant human sFasL can also serve as a useful tool with which to examine its pathological effects in an animal model system. Therefore it will be of interest to examine whether sFasL is present in the circulation of patients suffering from various diseases such as fulminant hepatitis or acquired immune deficiency syndrome.
Soluble Fas Ligand as a potential diagnostic tool
Initial clinical evidence suggests the importance of soluble Fas Ligand as a
novel biological predictor of the following diseases. All clinical results, mention
below, observed statistically significantly elevated level of sFasL in patients
compared with healthy donors.
- Sera from patients with large granular lymphocytic (LGL) leukemia and natural killer cell lymphoma
- The synovial fluid of inflamed joints of patients with Reumatoid arthritis (RA) and Osteoarthritis (OA)
- Pancreatic Carcinoma in tumor patients
- Acute graft-versus-host disease (aGVHD)
More Fas Ligand information and Scientific Background.
Collaboration Opportunity
SBH Sciences is looking for partners to investigate SBH Sciences fully functional soluble Fas Ligand as therapeutic agent as well as diagnostic tool. We are open for suggestions and would be pleased to hear from you.
|
|
